Liver fibrosis among infants with t(1;22)(p13;q13) acute megakaryoblastic leukemia: a case report and literature review.

acute megakaryoblastic leukemia liver fibrosis non-Down pediatric t(1;22)(p13;q13) translocation

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2024
Historique:
received: 30 05 2024
accepted: 24 07 2024
medline: 17 9 2024
pubmed: 17 9 2024
entrez: 16 9 2024
Statut: epublish

Résumé

This case report describes a 2-month-old girl with acute megakaryoblastic leukemia (AMKL) harboring the t(1;22)(p13;q13) translocation, resulting in the RBM15::MRTFA fusion gene. She presented with massive hepatosplenomegaly and liver fibrosis and achieved complete remission with chemotherapy; the liver fibrosis resolved within 2.5 months. After 12 years of follow-up, the patient remained in good health, without relapse. Reviewing the literature on eight additional similar cases of liver fibrosis, this subtype of AMKL predominantly affects female patients below 3 months of age, with a median onset at 6 weeks. High rates of severe complications were observed, with five of nine patients dying within 10 weeks of diagnosis. The authors hypothesized that the proliferation of abnormal megakaryoblasts within the liver leads to the release of profibrotic cytokines, such as TGF-β1, which induces liver fibrosis similar to that observed in transient abnormal myelopoiesis in Down syndrome. Careful monitoring of liver functions and reduced-intensity chemotherapy are recommended for this very young patient population. Nonetheless, long-term survival can be achieved with aggressive supportive care and treatment.

Identifiants

pubmed: 39281382
doi: 10.3389/fonc.2024.1441318
pmc: PMC11401043
doi:

Types de publication

Case Reports Journal Article

Langues

eng

Pagination

1441318

Informations de copyright

Copyright © 2024 Arad-Cohen, Attias, Zohar and Messinger.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Auteurs

Nira Arad-Cohen (N)

Pediatric Hematology-Oncology Department, Ruth Rappaport Children's Hospital, Rambam Health Care Campus, Haifa, Israel.

Ori Attias (O)

Pediatric Intensive Care Unit, Ruth Children's Hospital, Rambam Health Care Campus, Haifa, Israel.

Yaniv Zohar (Y)

Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Department of Pathology, Rambam Health Care Campus, Haifa, Israel.

Yoav H Messinger (YH)

Cancer and Blood Disorders, Pediatric Hematology/Oncology Department, Children's Minnesota, Minneapolis, MN, United States.

Classifications MeSH